about
Esomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsGender differences in aspirin use among adults with coronary heart disease in the United StatesLong-term continuation on cardiovascular drug treatment in patients with coronary heart diseaseAdherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.Ultrasound detection of increased carotid intima-media thickness and carotid plaque in an office practice setting: does it affect physician behavior or patient motivation?Prevalence and predictors of patient adherence to health recommendations after acute coronary syndrome: data for targeted interventions?Medication self-management skills and cognitive impairment in older adults hospitalized for heart failure: A cross-sectional study.Blood pressure control and antihypertensive pharmacotherapy patterns in a hypertensive population of Eastern Central Region of PortugalRecent hospitalization for non-coronary events and use of preventive medications for coronary artery disease: an observational cohort studyRisk factors for nonadherence to warfarin: results from the IN-RANGE study.Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital dischargeThe efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.Medication adherence: WHO cares?Underuse of medication for circulatory disorders among unmarried women and men in Norway?Risk of cardiovascular disease? A qualitative study of risk interpretation among patients with high cholesterol.Evidence of poor adherence to secondary prevention after acute coronary syndromes: possible remedies through the application of new technologiesCigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.Medication adherence mediates the relationship between marital status and cardiac event-free survival in patients with heart failureThe comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program.Exploring patients' reasons for discontinuance of heart medications.Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence.Use of medicines recommended for secondary prevention of acute coronary syndrome.Assessment of adherence to cardiovascular medicines in rural population: An observational study in patients attending a tertiary care hospital.Impact of a pay-for-performance intervention: financial analysis of a pilot program implementation and implications for ophthalmology (an American Ophthalmological Society thesis).Review article: how to control and improve adherence to therapy in inflammatory bowel disease.Role of the pharmacist.Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome.Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimenWhat factors contribute to the inadequate control of elevated blood pressure?The association of emotional well-being and marital status with treatment adherence among patients with hypertension.Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.Dispelling the myths about omega-3 fatty acids.Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoCan adherence to antihypertensive therapy be used to promote adherence to statin therapy?Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination.Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.MAT-CHDSP, a novel medication assessment tool for evaluation of secondary prevention of coronary heart disease.Optimal medical therapy, lifestyle intervention, and secondary prevention strategies for cardiovascular event reduction in ischemic heart disease.Management of antiplatelet therapy inpatients at risk for coronary StentThrombosis undergoing non-cardiac surgery.
P2860
Q26995752-FAC75D41-C016-491C-8300-500B990F98D6Q28220649-842500C7-C4B9-407D-8598-D8C4CF1CA3E7Q28220890-595AF538-F10A-4F9B-800A-C8E7A97EB975Q30248710-141051C3-7988-4A4E-BB7C-30DB9A12B2D0Q30370535-17756279-81E8-4636-9D37-0CC7470D97D2Q30584216-1B8C5675-E567-4201-96BA-22443BEAFFCBQ33694022-1E573E27-D065-48A7-BA36-3529B106F04FQ33782372-DBB204AD-67C8-4D3E-99D1-1716E78A1893Q33955960-01CBA5EA-122C-4D4B-8E9C-37D08ABA54E4Q34056085-71EAE964-40FD-4B35-82C5-D868E2EB9B22Q34274017-F057B0EB-55EA-43C6-AD3A-E2F405274F36Q34533125-D0A9D1B8-D386-4AD5-9C53-059460173D17Q34627451-52CC5298-C04C-48FE-9E85-4F418692F92DQ34794422-08748097-1EDB-4B3A-A582-77F2313C8283Q34990793-D2202288-5A42-4FDF-B95B-248AC1F5A48AQ35086213-F68B06C3-799E-440B-8658-40A5B13B5D63Q35234203-4574A731-85A8-47D9-B4C1-2C7A926AC9B6Q35783306-4AB89515-1DCA-423B-A87B-13BAE005D755Q35811990-E7A85722-0CC1-4E01-BC1B-318AC426C0A7Q35956390-A576239A-D95C-47A8-82EB-D65E1035C3EEQ36173141-943EA186-0811-4C79-9B0D-D525C183B436Q36395016-8F4F00A8-BDCF-48B8-8519-7C9892D4DA5DQ36398147-2A1A7036-EB71-43A0-BD91-494F45E5DE86Q36481853-296DBB05-C84A-4468-87FE-CB65C730C1D9Q36589420-394E6FFE-257B-4334-B16E-AFA31A74E6DEQ36662939-E6E4FD0A-62F0-4E4A-87B9-33336D188D54Q36792770-81D4826A-9151-4AE6-A5E5-21561EA2CC22Q36835874-D83EDF87-68C8-4493-B586-3B89CD017CA1Q37050151-141C63EB-DA9B-4FAB-B4CD-57885AD7C6EEQ37103791-884690C6-70D6-41CA-8DF3-1CD447F3C43EQ37148386-BB4B14D3-231F-4A35-B655-F656409E5A80Q37226404-34DEA020-7AF5-482A-B948-4370F3A62E47Q37373133-DCDA7BEF-14F3-4C68-820A-8ABEC8B35798Q37378896-0D82FD22-5271-4D75-8449-CF06810AA639Q37423691-078258C2-0F97-4459-8247-F2EF4C5F699CQ37423764-4177C8FA-EBD6-49ED-8ED2-7F2F120EC43AQ37532491-533A21EB-E32B-4C06-BBB0-AA81CD1D39BBQ37847120-5DB9AC2B-9B4F-4C72-822B-8F33EB97529AQ37873815-7DB3F9F7-9394-4DA4-9761-253233C9203CQ37937717-747FBD51-7619-4F94-9823-650B0DF55455
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Long-term adherence with cardiovascular drug regimens
@ast
Long-term adherence with cardiovascular drug regimens
@en
Long-term adherence with cardiovascular drug regimens
@nl
type
label
Long-term adherence with cardiovascular drug regimens
@ast
Long-term adherence with cardiovascular drug regimens
@en
Long-term adherence with cardiovascular drug regimens
@nl
prefLabel
Long-term adherence with cardiovascular drug regimens
@ast
Long-term adherence with cardiovascular drug regimens
@en
Long-term adherence with cardiovascular drug regimens
@nl
P2093
P1476
Long-term adherence with cardiovascular drug regimens
@en
P2093
Barbara Lytle
Karen P Alexander
Sonali P Kulkarni
P304
P356
10.1016/J.AHJ.2005.02.038
P407
P577
2006-01-01T00:00:00Z